In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.

Journal Article

CD26 is a M(r) 110,000 surface glycoprotein with diverse functional properties, including having a potentially significant role in tumor development, and antibodies to CD26 mediate pleomorphic cellular functions. In this report, we show that binding of soluble anti-CD26 monoclonal Ab 1F7 inhibits the growth of the human CD30+ anaplastic large cell T-cell lymphoma cell line Karpas 299 in both in vitro and in vivo experiments. In vitro experiments show that 1F7 induces cell cycle arrest at the G1-S checkpoint, associated with enhanced p21 expression that is dependent on de novo protein synthesis. Furthermore, experiments with a severe combined immunodeficient mouse tumor model demonstrate that 1F7 treatment significantly enhances survival of tumor-bearing mice by inhibiting tumor formation. Our data therefore suggest that anti-CD26 treatment may have potential clinical use for CD26+ hematological malignancies.

Duke Authors

Cited Authors

  • Ho, L; Aytac, U; Stephens, LC; Ohnuma, K; Mills, GB; McKee, KS; Neumann, C; LaPushin, R; Cabanillas, F; Abbruzzese, JL; Morimoto, C; Dang, NH

Published Date

  • July 2001

Published In

Volume / Issue

  • 7 / 7

Start / End Page

  • 2031 - 2040

PubMed ID

  • 11448921

International Standard Serial Number (ISSN)

  • 1078-0432

Language

  • eng